Zura Bio Limited (ZURA) News
Follow Zura Bio Limited (ZURA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ZURA nears pivotal-trial readouts for IL-17/BAFF bispecific in autoimmunity
ZURA says upcoming pivotal-trial data in hidradenitis suppurativa and systemic sclerosis will test a bispecific antibody targeting IL-17 and BAFF, aiming to address efficacy ceilings in autoimmune diseases.
EQUITY | Sep 09, 2026, 02:59 PM UTC
M
ZURA advances tibulizumab dual-target bispecific in autoimmune pivotal trials
ZURA is advancing a multifunctional antibody pipeline, with tibulizumab leading pivotal trials for hidradenitis suppurativa and systemic sclerosis. The bispecific targets IL-17 and BAFF for potential superior efficacy, w
EQUITY | Sep 09, 2026, 02:07 PM UTC
L
Zura Bio to Participate in the Cantor Global Healthcare Conference
Zura Bio to Participate in the Cantor Global Healthcare Conference
EQUITY | Aug 31, 2026, 08:30 PM UTC
L
Wedbush Reiterates Outperform on Zura Bio, Maintains $15 Price Target
Wedbush analyst Martin Fan reiterates Zura Bio (NASDAQ: ZURA ) with a Outperform and maintains $15 price target.
EQUITY | Jul 01, 2026, 01:56 PM UTC